The FDA has approved lonvoguran ziclumeran (lonvo-z), Intellia Therapeutics’ one-time, in vivo mRNA-lipid nanoparticle genome-editing treatment for hereditary angioedema (HAE), after the program cleared Phase III. The approval follows the HAELO trial (NCT06634420), with efficacy data published in the New England Journal of Medicine. The therapy targets the disease biology by editing the genetic driver underlying HAE, aiming to reduce the frequency and severity of unpredictable swelling attacks that can become disfiguring or life-threatening, particularly when airway involvement occurs. Clinicians have also emphasized the psychosocial impact of recurrence uncertainty as part of the disease burden. For biotech and platform developers, the signal is that in vivo CRISPR with mRNA/LNP delivery is reaching commercialization milestones, moving from trial to regulatory validation. It also raises competitive pressure for other gene-editing modalities targeting autosomal diseases. (Selected item reflects the FDA clearance and Phase III context.)